SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas.
We are developing our lead product candidate, SCY-078, a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections.
|Feb 1, 2018
SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
|Jan 11, 2018
SCYNEXIS to Participate in the Cantor Antibiotics Summit
|Jan 4, 2018
SCYNEXIS Provides Corporate and SCY-078 Pipeline Update